Ventus Therapeutics Inc. has announced the development of VENT-03, a potential first-in-class drug designed to target cGAS, a cell receptor linked to lupus and a broad range of other diseases including neuroinflammatory and neurodegenerative diseases. This will be the first drug of its kind to advance into clinical development, and it will enter its first Phase I trial cGAS is thought to be involved in both systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE), and the latest news marks an exciting step forward in lupus drug development.
Last year, Ventus received a Lupus Research Program Idea Award from the U.S. Department of Defense (DoD) to study the cGAS inhibitor as a potential treatment for lupus. The Lupus Foundation of America’s (LFA) advocacy efforts and strong community of advocates led the fight in establishing the DoD Lupus Research Program in 2017, successfully advocating each year for continued funding of this critical program. To date, the program has provided more than $76 million to fund high-impact, high-quality studies to help find ways to diagnose and treat lupus more effectively.
Continue to follow the LFA for updates on VENT-03 and learn more about medications used to treat lupus.
Article Credit: Lupus Foundation of America | lupus.org